Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1

Clinical and Experimental Immunology

Volumn 129, Issue 3, 2002, Pages 527-532

  Waterman, E A ^a   Kemp, E H ^a   Gawkrodger, D J ^b   Watson, P F ^a   Weetman, A P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Autoantibody; Autoantigen; Autoimmunity; Melanocyte; Vitiligo

Indexed keywords

AUTOANTIBODY; DIFFERENTIATION ANTIGEN; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; MELAN A; SULFUR 35;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BINDING ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; PRIORITY JOURNAL; RADIOASSAY; VITILIGO; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BLOTTING, WESTERN; CELL DIFFERENTIATION; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MELANOCYTES; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN BIOSYNTHESIS; RADIOLIGAND ASSAY; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; VITILIGO;

EID: 0036037596     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01949.x     Document Type: Article

References (39)

1. Vitiligo in Graves' disease
2. Vitiligo and juvenile diabetes mellitus
3. Antibodies to normal human melanocytes in vitiligo
4. The significance of vitiligo antibodies
5. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
6. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1
7. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo
8. Identification of pigment cell antigens defined by vitiligo antibodies
9. Characterisation of vitiligo antigens
10. The role of tyrosinase in autoimmune vitiligo
11. Tyrosinase as an autoantigen in patients with vitiligo
12. 35S-labelled recombinant human tyrosinase in a radioimmunoassay
13. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay
14. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy
15. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: Evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2)
16. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: A sensitive and quantitative radioimmunoassay (RIA)
17. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I
18. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo
19. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo
20. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo
21. Evidence for immunologic mechanisms in human vitiligo. Patients' sera induce damage to human melanocyes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity
22. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo
23. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase
24. Identification of epitopes on tyrosinase which are recognised by autoantibodies from patients with vitiligo
25. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas
26. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
27. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
28. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
29. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
30. High frequencies of naive Melan-A/MART-1-specific CD8 (+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
31. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
32. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
33. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
34. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
35. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses
36. Melanoma-associated hypopigmentation: Where are the antibodies?
37. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: A comparison to radioreceptor assay and thyroid stimulating bioassay
38. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis